I'd like to remind everyone, and any new investors who may be reading and not posting, that Leo has stated many times over the years that CTIX was not looking to partner or sell their drugs until they felt that they have maximized the value of them. I am sure it is highly likely that CTIX could partner or sell just about any of the drugs right now, as-is, but they will not receive as good a price for them as they will with the later stage trial data. Plus as the drugs succeed in later trials risk is reduced, and reduced risk for BP is worth lots of additional money. Leo is a shareholder and Menon is a shareholder; if they are confident that the drugs are working well, and that they have enough funding to continue pursuing trials for the next year, what motivation do they have to diminish potentially massive value just for the sake of partnership in the short term?
I am fully aware that CTIX does not currently have the funding to get any of the drugs through a phase 3 and to market, but they have sufficient funds for a year (even at current share prices) to continue trials and increase the value of the drugs for the future partnership/sale. Yes, more money now may allow for more speed on development, but that will likely only be through a crappy deal and defeat the purpose of maximizing value. Plus, if the plan reaches its time limit and doesn't work to get a better deal, then that tells me the management's backup scenario is that they will then partner or sell a drug for less money in order to keep solvent. It would not be ideal to have to do that, but I think that is a worthwhile gamble for the potential of stellar returns upon future trial success.
This is why I do not put any weight to the continued statements that CTIX can't find a partner, or that Leo has screwed up, or that somehow they are going to go bankrupt. They are choosing to continue down this short term path (which I admit is painful as a shareholder to see paper losses) in order to create a better long term gain for all of us.